Jacob S Aday
Overview
Explore the profile of Jacob S Aday including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aday J, Mason N, Wood B, Kramer H, Ortiz C, Vest M, et al.
Psychedelic Med (New Rochelle)
. 2025 Mar;
2(1):44-59.
PMID: 40051758
No abstract available.
2.
Aday J, Skiles Z, Eaton N, Fredenburg L, Pleet M, Mantia J, et al.
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(1):27-37.
PMID: 40047007
Background: An emerging controversy in psychedelic therapy regards the appropriateness or necessity of psychedelic therapists having personal experience using psychedelics themselves. Although there are a number of potential advantages and...
3.
Aday J, Barnett B, Grossman D, Murnane K, Nichols C, Hendricks P
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(3):150-165.
PMID: 40046566
Background: In the wake of positive clinical trial outcomes of psychedelic-assisted psychotherapy for the treatment of various psychiatric disorders, there has been an influx of financial investment into psychedelic drug...
4.
Glynos N, Baker A, Aday J, Kruger D, Boehnke K, Lake S, et al.
Br J Pain
. 2025 Feb;
:20494637251319497.
PMID: 39944237
Psychedelic substances have shown preliminary efficacy for several neuropsychiatric disorders and are currently being investigated for chronic pain conditions. However, few studies have investigated outcomes of naturalistic psychedelic use among...
5.
Kruger D, Albrecht J, Aday J, Barron J, Herberholz M, Boehnke K
J Psychoactive Drugs
. 2025 Feb;
:1-7.
PMID: 39907623
Psychedelic drugs are currently being explored for their therapeutic potential for a variety of health conditions. The recent increased public interest in psychedelics necessitates empirical investigation into motivations for use...
6.
Glynos N, Baker A, Aday J, Pouyan N, Barron J, Herberholz M, et al.
J Psychoactive Drugs
. 2024 Sep;
:1-11.
PMID: 39297183
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report naturalistic psychedelic use with so-called "underground" practitioners, little is known about PAT that...
7.
Peled-Avron L, Aday J, Kalafateli A, Hamilton H, Woolley J
Front Psychiatry
. 2024 Jun;
15:1431389.
PMID: 38915850
No abstract available.
8.
Aday J, Horton D, Fernandes-Osterhold G, ODonovan A, Bradley E, Rosen R, et al.
Psychopharmacology (Berl)
. 2024 May;
241(8):1517-1526.
PMID: 38782821
Rationale: Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance...
9.
Glynos N, Aday J, Kruger D, Boehnke K, Lake S, Lucas P
Front Psychiatry
. 2024 Mar;
15:1349565.
PMID: 38455520
Introduction: Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date have been limited by small sample sizes and...
10.
Aday J, Bloesch E, Davis A, Domoff S, Scherr K, Woolley J, et al.
J Psychoactive Drugs
. 2024 Feb;
:1-10.
PMID: 38310541
Qualitative studies and anecdotal reports suggest that experiences with ayahuasca, a psychedelic brew found in Central and South America, may be followed by individuals enduringly feeling more grateful and connected...